Compare USA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USA | ANIP |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 1999 |
| Metric | USA | ANIP |
|---|---|---|
| Price | $5.97 | $76.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.1M | 303.5K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | $15.77 |
| P/E Ratio | ★ N/A | $22.86 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $5.64 | $56.71 |
| 52 Week High | $6.96 | $99.50 |
| Indicator | USA | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 45.24 |
| Support Level | $5.93 | $75.20 |
| Resistance Level | $6.09 | $85.12 |
| Average True Range (ATR) | 0.07 | 2.72 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 52.00 | 54.24 |
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.